News 2010
November 05, 2010
Three clinics within UHealth–the University of Miami Health System have been recognized for their “statistically significant improvement” in patient satisfaction by Press Ganey, the national patient perception research and quality improvement-tracking firm. This has provided an overall boost for the entire health system, which also was highly ranked by Press Ganey.
Read more about the Miller School's Press Ganey ratings »
November 04, 2010
On Thursday, Nov. 4, 2010, Andrew Pollack of the New York Times wrote an article describing a secret rebate program between the pharmaceutical company Genentech and select eye doctors throughout the country. In this program, eye doctors are offered a financial kick-back if they increase their use of an expensive eye drug known as Lucentis to treat patients who have the wet form of age-related macular degeneration (AMD). Lucentis was approved by the FDA in 2006 to treat this blinding disease. Some patients with this condition require repeated injections of this drug for many years at a cost of approximately $2,000 per injection. The ophthalmologists at the University of Miami’s Bascom Palmer Eye Institute have not participated in this program and will never accept any type of financial kick-back designed to influence patient care.